306 related articles for article (PubMed ID: 25785448)
1. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
[TBL] [Abstract][Full Text] [Related]
2. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
[TBL] [Abstract][Full Text] [Related]
3. Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy.
Vesterbacka J; Barqasho B; Häggblom A; Nowak P
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):830-6. PubMed ID: 26059763
[TBL] [Abstract][Full Text] [Related]
4. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).
Viladés C; Escoté X; López-Dupla M; Martinez E; Domingo P; Asensi V; Leal M; Peraire J; Inza MI; Arnedo M; Gutiérrez M; Valle-Garay E; Ferrando-Martinez S; Olona M; Alba V; Sirvent JJ; Gatell JM; Vidal F;
J Antimicrob Chemother; 2014 Jun; 69(6):1653-9. PubMed ID: 24535275
[TBL] [Abstract][Full Text] [Related]
6. CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.
Kared H; Saeed S; Klein MB; Shoukry NH
PLoS One; 2014; 9(7):e101441. PubMed ID: 25007250
[TBL] [Abstract][Full Text] [Related]
7. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.
Abad-Fernández M; Vallejo A; Hernández-Novoa B; Díaz L; Gutiérrez C; Madrid N; Muñoz MA; Moreno S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):149-53. PubMed ID: 24047967
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Rivero-Juarez A; Neukam K; Labarga P; Camacho A; Macias J; Barreiro P; Torre-Cisneros J; Pineda JA; Soriano V; Rivero A
J Infect; 2014 Apr; 68(4):372-7. PubMed ID: 24269677
[TBL] [Abstract][Full Text] [Related]
9. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
[TBL] [Abstract][Full Text] [Related]
10. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
[TBL] [Abstract][Full Text] [Related]
11. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
12. Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.
Vargas A; Berenguer J; Catalán P; Miralles P; López JC; Cosín J; Resino S
J Antimicrob Chemother; 2010 Feb; 65(2):303-6. PubMed ID: 20016018
[TBL] [Abstract][Full Text] [Related]
13. High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.
Nien HC; Hsu SJ; Su TH; Yang PJ; Sheu JC; Wang JT; Chow LP; Chen CL; Kao JH; Yang WS
PLoS One; 2017; 12(1):e0170028. PubMed ID: 28107471
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
Krastinova E; Bani-Sadr F; Fromentin D; Goujard C; Hessamfar M; Yazdanpanah Y; Pol S; Cacoub P; Perronne C; Carrat F
J Infect; 2014 May; 68(5):462-6. PubMed ID: 24378283
[TBL] [Abstract][Full Text] [Related]
15. Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.
Tudesq JJ; Dunyach-Remy C; Combescure C; Doncesco R; Laureillard D; Lavigne JP; Sotto A
PLoS One; 2017; 12(9):e0183372. PubMed ID: 28934209
[TBL] [Abstract][Full Text] [Related]
16. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
[TBL] [Abstract][Full Text] [Related]
20. Markers of microbial translocation during pregnancy: differences among HIV+ women of African and European provenance.
Baroncelli S; Galluzzo CM; Molinari A; Pirillo MF; Cavalli A; Negri E; Floridia M; Degli Antoni A
J Infect Dev Ctries; 2020 Feb; 14(2):184-190. PubMed ID: 32146453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
